Micro-Tech (Nanjing) Co., Ltd.

Micro-Tech (Nanjing) Co., Ltd. faced a significant decline in stock value on July 17, 2026, reaching an intraday low. Year-to-date, the stock has decreased, and its annual performance lags behind the broader market. Despite these challenges, the company retains a substantial market capitalization and offers a dividend yield.

Micro-Tech (Nanjing) Co., Ltd. saw a significant stock increase today, contrasting with the broader market's modest gains. While the company has shown strong weekly growth, its monthly performance indicates volatility. With a solid market capitalization and positive long-term growth metrics, strategic focus may be necessary for future stability.

Micro-Tech (Nanjing) Co., Ltd. has seen a significant rise today, contrasting with a decline in the broader market. Despite recent fluctuations, the company maintains a market capitalization of CNY 13,131 million, a price-to-earnings ratio of 23.00, and a dividend yield of 2.11%.

Micro-Tech (Nanjing) Co., Ltd. faced a decline in stock performance, contrasting with the China Shanghai Composite's slight decrease. The company has experienced significant downturns over various timeframes, including a year-to-date drop. Despite these challenges, it maintains a substantial market capitalization and offers a dividend yield.

Micro-Tech (Nanjing) Co., Ltd. experienced notable stock activity today, reaching an intraday high and outperforming the China Shanghai Composite index over the past week. Despite recent challenges, the company maintains a strong market position with solid financial metrics and a commitment to shareholder returns.

Micro-Tech (Nanjing) Co., Ltd. saw a significant intraday rise on March 24, 2026, despite recent challenges, including a decline over the past week and month. The company has a market capitalization of CNY 14,609 million, with a return on equity of 15.57% and a dividend yield of 1.89%.

Micro-Tech (Nanjing) Co., Ltd. faced a notable decline in its stock price, reflecting a challenging trading environment. Over the past month, the stock has decreased significantly, contrasting with the broader market's performance. The company maintains a substantial market capitalization and various financial metrics that highlight its complex situation.

Micro-Tech (Nanjing) Co., Ltd. faced a significant stock decline today, contrasting with the broader market's performance. The company has experienced a notable downturn over the past week and year-to-date, with long-term performance showing a substantial drop compared to the China Shanghai Composite. It operates in the Pharmaceuticals & Biotechnology sector.

Micro-Tech (Nanjing) Co., Ltd. saw a significant increase on February 25, 2026, contrasting with a decline in the China Shanghai Composite index. Despite a challenging month, the company has shown resilience with a year-to-date performance of 0.69% and a notable annual return of 17.84%.

Micro-Tech (Nanjing) Co., Ltd. saw a notable decline in stock performance, dropping 7.29% on October 14, 2025. Despite recent challenges, the company has a strong year-to-date increase of 34.12% and a solid market capitalization of CNY 16,642 million, with key financial indicators reflecting its robust position in the Pharmaceuticals & Biotechnology sector.

Micro-Tech (Nanjing) Co., Ltd. saw a notable decline in its stock today, contrasting with the broader market's performance. Despite recent setbacks, the company has shown strong annual returns and solid financial metrics, including a significant market capitalization and a commitment to shareholder value through dividends.

Micro-Tech (Nanjing) Co., Ltd. saw a decline in stock price today, contrasting with the broader market's performance. Despite this, the company has achieved a significant annual return and maintains strong financial metrics, including a solid return on equity and robust operating cash flow, reflecting effective resource management.

Micro-Tech (Nanjing) Co., Ltd. experienced notable stock activity, rising significantly today and achieving an intraday high. The company has shown strong performance over the past week and year, outperforming the China Shanghai Composite. Key financial metrics indicate a solid operational position within the Pharmaceuticals & Biotechnology industry.